Key facts
- Lumen Bioscience’s last known valuation is $92.8M (Sep 2020).
- It has raised $111.0M; the latest was Later Stage VC ($30.0M) in Oct 2025.
- Notable investors include U.S. Department of Energy, National Institutes of Health, Gates Foundation, United States Department of Agriculture, CARB-X — 18 tracked in total.
- Lumen Bioscience has filed 5 Form Ds with the SEC since 2019, most recently Apr 2025 ( sold).
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Lumen Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Lumen Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lumen Bioscience
Operator of a biosciences company intended to develop biologic drugs faster than traditional ways. The company discovers, and develops biological drugs for several prevalent, worldwide diseases that currently lack any effective treatments through technology that increases speed, mass-market scale and lower costs than current approaches, enabling clinicians to have access to innovative treatments for ailments currently lacking effective options.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2017
- Employees
- 101
- Website
- lumen.bio/
- Ownership
- Privately Held (backing)
Lumen Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lumen Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lumen Bioscience in its N-PORT filings yet. We sweep new filings monthly.